Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Genetics, HLB Sign Manufacturing Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Atossa Genetics today announced a manufacturing agreement with HLB for its Mammary Aspirate Specimen Cytology Test for field testing before commercial launch.

Financial terms of the deal were not disclosed.

MASCT is a medical device and method for collecting, shipping, and clinically analyzing nipple aspirate fluid, which contains cells and molecular diagnostic markers that can be used to detect breast cancer as well as cellular changes that may be precursors to breast cancer. The system has been cleared by the US Food and Drug Administration.

The Seattle-based molecular diagnostics company said that it plans to launch MASCT in the Pacific Northwest this year with a wider release in 2012.

Atossa filed for an initial public offering in the fall but withdrew it in February.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.